U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26 books (79 items)

1.
Belimumab (Benlysta): CADTH Reimbursement Recommendation: Indication: In addition to standard therapy for treatment of active lupus nephritis in adult patients [Internet].

Belimumab (Benlysta): CADTH Reimbursement Recommendation: Indication: In addition to standard therapy for treatment of active lupus nephritis in adult patients [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Feb.

Table of Contents

2.
Pembrolizumab (Keytruda): CADTH Reimbursement Review: Therapeutic area: Triple-negative breast cancer [Internet].

Pembrolizumab (Keytruda): CADTH Reimbursement Review: Therapeutic area: Triple-negative breast cancer [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Mar.

Table of Contents

3.
Chronic Heart Failure in Adults: Diagnosis and Management.

Chronic Heart Failure in Adults: Diagnosis and Management.

National Guideline Centre (UK).

London: National Institute for Health and Care Excellence (NICE); 2018 Sep. (NICE Guideline, No. 106.)

Table of Contents

4.
Cystic Fibrosis: Diagnosis and management.

Cystic Fibrosis: Diagnosis and management.

National Guideline Alliance (UK).

London: National Institute for Health and Care Excellence (NICE); 2017 Oct 25. (NICE Guideline, No. 78.)

Table of Contents

5.
Anifrolumab (Saphnelo): CADTH Reimbursement Recommendation: Indication: in addition to standard therapy for the treatment of adult patients with active, autoantibody positive, systemic lupus erythematosus [Internet].

Anifrolumab (Saphnelo): CADTH Reimbursement Recommendation: Indication: in addition to standard therapy for the treatment of adult patients with active, autoantibody positive, systemic lupus erythematosus [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Feb.

Table of Contents

6.
Practical Approaches to Managing Advanced Kidney Cancer: Version 2020 [Internet].

Practical Approaches to Managing Advanced Kidney Cancer: Version 2020 [Internet].

Rendon R, Kapoor A, authors; Heng DYC, Kollmannsberger C, editors.

Dorval (QC): Canadian Urological Association; 2020.

Table of Contents

7.
Drug Allergy: Diagnosis and Management of Drug Allergy in Adults, Children and Young People.

Drug Allergy: Diagnosis and Management of Drug Allergy in Adults, Children and Young People.

National Clinical Guideline Centre (UK).

London: National Institute for Health and Care Excellence (NICE); 2014 Sep. (NICE Clinical Guidelines, No. 183.)

Table of Contents

8.
PDQ Cancer Information Summaries [Internet].

PDQ Cancer Information Summaries [Internet].

Bethesda (MD): National Cancer Institute (US); 2002-.

Table of Contents

9.
Blood Donor Selection: Guidelines on Assessing Donor Suitability for Blood Donation.

Blood Donor Selection: Guidelines on Assessing Donor Suitability for Blood Donation.

Geneva: World Health Organization; 2012.

Table of Contents

10.
Acute kidney injury: prevention, detection and management.

Acute kidney injury: prevention, detection and management.

London: National Institute for Health and Care Excellence (NICE); 2023 Sep 28. (NICE Guideline, No. 148.)

Table of Contents

11.
Intrapartum care for women with existing medical conditions or obstetric complications and their babies.

Intrapartum care for women with existing medical conditions or obstetric complications and their babies.

London: National Institute for Health and Care Excellence (NICE); 2019 Mar 6. (NICE Guideline, No. 121.)

Table of Contents

12.
Michigan Medicine Inpatient Diuretic Guideline for Patients with Acute Decompensated Heart Failure [Internet].

Michigan Medicine Inpatient Diuretic Guideline for Patients with Acute Decompensated Heart Failure [Internet].

Konerman MC, Bozaan DA, Adie S, et al.

Ann Arbor (MI): Michigan Medicine University of Michigan; 2022 Dec.

Table of Contents

13.
Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient endometrial cancer whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy [Internet].

Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient endometrial cancer whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Feb.

Table of Contents

14.
Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with high-risk early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery [Internet].

Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with high-risk early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Sep.

Table of Contents

15.
Comparing Medicines for Long-Term Treatment of Bipolar Disorder [Internet].

Comparing Medicines for Long-Term Treatment of Bipolar Disorder [Internet].

Nestsiarovich A, Hurwitz NG, Kerner B, et al.

Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2021 Mar.

Table of Contents

16.
Incorporating Alcohol Pharmacotherapies Into Medical Practice.

Incorporating Alcohol Pharmacotherapies Into Medical Practice.

Center for Substance Abuse Treatment.

Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2009. (Treatment Improvement Protocol (TIP) Series, No. 49.)

Table of Contents

17.
Cemiplimab (Libtayo): CADTH Reimbursement Recommendation: Indication: First-line treatment of adult patients with non–small cell lung cancer (NSCLC) expressing PD-L1 (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK, or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC [Internet].

Cemiplimab (Libtayo): CADTH Reimbursement Recommendation: Indication: First-line treatment of adult patients with non–small cell lung cancer (NSCLC) expressing PD-L1 (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK, or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jun.

Table of Contents

18.
Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indication: Treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (combined positive score ≥ 1), as determined by a validated test, in combination with chemotherapy with or without bevacizumab [Internet].

Pembrolizumab (Keytruda): CADTH Reimbursement Recommendation: Indication: Treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (combined positive score ≥ 1), as determined by a validated test, in combination with chemotherapy with or without bevacizumab [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Dec.

Table of Contents

19.
Guidelines for drinking-water quality: Fourth edition incorporating the first and second addenda [Internet].

Guidelines for drinking-water quality: Fourth edition incorporating the first and second addenda [Internet].

Geneva: World Health Organization; 2022.

Table of Contents

20.
World Report on Child Injury Prevention.

World Report on Child Injury Prevention.

Peden M, Oyegbite K, Ozanne-Smith J, et al., editors.

Geneva: World Health Organization; 2008.

Table of Contents

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Search details

See more...

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...